Even if they provide an update at ASH 2026 I don't see it moving the needle much. I'd view it as meaningful if they report (very) high responses (ideally deep) in a refractory population, the responses are durable, and the safety profile is clean.
The want to complete dose escalation cohorts of FT836 in solid tumours by mid 2026 (I put that up to Q3 2026).
They also want to complete phase one SLE cohort enrollment by mid-2026 and activate up to forty sites for pivotal trial readiness. Also gain FDA alignment on registrational protocol and initiate a pivotal trial in 2026 as well.
Market Data 
Markets 
AI
